Nathan Walcker

As the Chief Executive Officer of Florida Cancer Specialists & Research Institute (FCS), Nathan H. Walcker oversees implementation of the organization’s mission to provide world-class cancer care, close to home in community-based settings across the state of Florida. He leads the development of strategic initiatives that continue to drive FCS forward as a national cancer care leader.

His top priorities as CEO are three-fold:

• Ensuring that patients battling cancer receive the highest quality clinical care with convenient access to innovative treatment options and therapies
• Investing in early-phase drug development, first-in-human clinical trials, research and novel treatments
• Delivering a relentless focus on operational, clinical and financial excellence

Walcker joined FCS in 2019 as Chief Financial Officer, bringing more than a decade of diverse healthcare, physician services and corporate finance expertise with him. He was appointed CEO of the statewide practice in 2020.

Previously, he served as a key member of Bank of America Merrill Lynch’s Global Healthcare Investment Banking group in New York, advising the firm’s public and emerging growth health care clients and leading private equity firms. Walcker began his career on Wall Street on the Merrill Lynch trading floor in New York and went on to assume increasing responsibilities as an investment banker and strategic advisor to corporations, entrepreneurs and public company boards. Walcker earned an MBA from Columbia Business School and a bachelor’s degree in economics from Columbia University.

Since joining FCS, Walcker has made significant contributions across finance and accounting operations, business planning and strategy, and fiscal compliance policy and practices. His exceptional healthcare and financial background, coupled with his strategic leadership, has served to guide the company through the COVID-19 pandemic, several hurricanes, national drug shortages and a nationwide clearinghouse shutdown to ensure the continuation of patient care with minimal disruption.

Further, Walcker has championed new innovations and strategies, such as the implementation of telehealth visits, the development of a precision oncology platform, the establishment of FCS’ management services organization, Core Ventures and its data insights subsidiary, Vita Nova Insights,^SM the deployment of the FCS Holistic Model of Care,  and the integration of dozens of new locations and physicians. He has also maintained the organization’s long-term focus and commitment to bringing clinical research and trial opportunities to FCS patients throughout the state.

Making a difference and driving change is critically important to Walcker, who is inspired daily by the dedication and commitment of the more than 4,700 FCS team members in 100 locations across Florida. He says. “Our shared commitment to patient care, quality, innovation and teamwork drives all that we do at FCS.”

Deeply committed to community service, Walcker has served on several community boards and forums, including the American Cancer Society’s CEOs Against Cancer, the Health Evolution Forum, and Lime Connect, a nonprofit that connects high-potential students and professionals with disabilities with professional development opportunities.

In 2024, he was named one of the Top 500 Most Influential Executives in Florida by Florida Trend as well as a recipient of the 40 Under 40 in Cancer Award, one of 40 leaders selected from across the nation by The Association for Value-Based Cancer Care (AVBCC), NCODA and other sponsors for significant contributions in the field of oncology. Nate was named a 2022 Tampa Bay Business Journal’s 40 Under 40 honoree, selected out of nearly 500 qualified nominations in the Tampa Bay area.